Stockreport

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Vir Biotechnology, Inc.  (VIR) 
PDF – License of proprietary masking platform further strengthens Vir’s drug discovery capabilities in oncology and infectious disease –– Strategic agreement expands Vir por [Read more]